X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.biospace.com/article/fda-blocks-alnylam-s-bid-to-expand-onpattro-into-attr-cardiomyopathy/
https://endpts.com/ahead-of-adcomm-fda-questions-efficacy-of-alnylams-patisiran-in-disabling-rare-condition-attr-cm/
https://www.fiercepharma.com/pharma/chasing-pfizer-alnylam-face-fda-adcom-onpattros-rare-heart-disease-bid
https://www.fiercepharma.com/pharma/alnylams-new-onpattro-data-raise-fresh-commercial-doubt-heart-disease-fight-against-pfizer
https://www.investors.com/news/technology/alnylam-stock-surges-to-record-high-as-cardiomyopathy-drug-looks-to-take-on-pfizer/
https://www.fiercepharma.com/pharma/eying-pfizer-alnylams-high-stakes-onpattro-attr-heart-trial-delivers-partial-win-misses-key
https://www.biospace.com/article/releases/onpattro-and-174-patisiran-now-reimbursed-in-canada-for-the-treatment-of-hereditary-transthyretin-ttr-mediated-amyloidosis-hattr-/?s=71
https://www.fiercepharma.com/pharma/alnylam-hit-doj-subpoena-over-onpattro-marketing
https://www.fiercepharma.com/marketing/alnylam-s-onpattro-back-game-ionis-thanks-to-nice-u-turn?utm_source=internal&utm_medium=rss
http://www.pmlive.com/pharma_news/akcea_steals_march_on_alnylam_with_nice_approval_1284584
http://www.bioworld.com/perspectives/2018/12/28/bioworlds-top-10-biggest-newsmakers-and-trending-stories-of-2018/
https://www.genengnews.com/lists/5-biopharma-trends-to-watch-in-2019/
https://www.biopharmadive.com/news/alnylam-ceo-talks-politics-gene-therapy-and-not-becoming-pfizer/544298/
http://www.pharmafile.com/news/519638/nice-reject-two-treatments-fatal-ultra-rare-disease-hattr
https://www.fiercepharma.com/marketing/alnylam-s-onpattro-sales-look-disappointing-early-days-rnai-launch-analyst
https://www.ema.europa.eu/documents/product-information/onpattro-epar-product-information_en.pdf
https://www.xconomy.com/boston/2018/10/15/alnylam-wont-seek-quick-fda-nod-for-second-rnai-drug/
https://seekingalpha.com/article/4208734-alnylam-pharmaceuticals-use-straightforward-good-news
http://www.pharmatimes.com/news/alnylams_rna_therapy_onpattro_bags_eu_nod_1250846
https://www.fiercepharma.com/marketing/novartis-and-gilead-s-car-ts-ultragenyx-s-mepsevii-and-more-rack-up-eu-approvals
http://www.pharmatimes.com/news/fda_rejects_akceaionis_rare_disease_drug_waylivra_1250346
https://seekingalpha.com/article/4202552-approval-labeling-pricing-competitor-data-give-alnylam-pharmaceuticals-wild-ride
https://www.fiercepharma.com/marketing/pfizer-s-tafamidis-score-still-leaves-door-open-for-alnylam-rival-analysts
https://www.fiercebiotech.com/biotech/pfizer-eyes-attr-cardiomyopathy-filing-for-tafamidis-after-acing-phase-3-trial
https://www.fiercepharma.com/marketing/esc-need-to-know-xarelto-flops-pfizer-s-tafamidis-win-entresto-s-early-use-and-more
Market Place
Share 
